Graftable

Graftable is an early-stage biotech focused on tissue engineering for improved injury repair. The company's mission is to enable faster healing with less scarring and tissue loss, targeting significant unmet needs in post-traumatic, post-surgical, and post-cancer resection wound care. While still in a pre-clinical/pre-revenue stage, its platform technology holds promise for both aesthetic/functional skin repair and complex cell transplantation. The company appears to be privately held and in a foundational phase of technology development.

A biomaterial-based platform designed to modulate the wound microenvironment to promote tissue regeneration over scarring, with potential application as a delivery vehicle for metabolically-demanding cell types like pancreatic islets or adipocytes.

Graftable operates in a competitive field including established wound care companies (e.g., Integra LifeSciences, Organogenesis), biotech firms developing advanced biomaterials (e.g., TISSIUM, 3M's Acelity), and numerous startups in regenerative medicine. Differentiation will require demonstrating superior clinical outcomes in scarring and function. In cell delivery, it would compete with encapsulation device companies like ViaCyte (now CRISPR Therapeutics) and Sernova.